Ovid Therapeutics announced on July 5, 2026, that its Chief Business & Financial Officer, Jeffrey Rona, is stepping down effective July 6, under a mutual agreement. The company immediately promoted Charles Carter, its SVP of Finance and Financial Planning, to CFO, principal accounting officer, and secretary. Carter will earn a $460,000 base salary with a 35% target bonus, a $75,000 additional cash bonus, and a restricted stock award of 50,000 shares vesting over two years.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding OVID THERAPEUTICS INC (OVID)?

Major stakeholders currently include Ra Capital Management, L.p. ($23.8M), Janus Henderson Group PLC ($23.7M), Affinity Asset Advisors, LLC ($23.6M). Based on the latest 13F filings, there are a total of 103 tracked investment funds and institutions maintaining positions in OVID.

What is the overall institutional sentiment toward OVID recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $133.0M, driven by 60 managers accumulating shares while 30 reduced their exposure.

Which institutions have been selling or reducing their OVID positions?

In the latest period, 21 funds trimmed their holdings, and 9 managers completely exited their positions. The aggregate reported sell value was $25.2M.

Are there any notable investors adding OVID to their portfolios?

Yes, buying activity remains notable. 27 institutions opened new positions in {ticker}, and 33 existing holders added to their shares. The total reported buy value for the quarter amounted to $170.9M.